Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...

Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...

Pfizer’s PFE non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products ...

Dividend stocks can be a great way to boost your portfolio's growth potential or provide a form of passive income over the ...

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen ...

Diabetes and weight management drugs dominated game-day NFL advertising during the regular season, with TV outcomes company ...

Some stocks pay juicy dividends for a while only for the income to later dwindle. Others generate consistent and reliable ...

Also Read: Pfizer's Paxlovid Demonstrates Safety But ... that traditional medical records may overlook. Extended antiviral courses have precedent in other conditions like HIV and hepatitis C ...

Growth was definitely bound to normalize and even experience volatility once sales of Comirnaty (its blockbuster COVID-19 vaccine) and oral antiviral drug waned. Let's take a look at where Pfizer ...

Drugmakers have raised the list prices of more than 800 prescription drugs — ranging from blood pressure medications to cancer treatments — by a median of 4% at the start of this year, The Wall Street ...